Back

Vicore Pharma’s Annual Report 2018 published

Mölndal, April 12, 2019 – Vicore Pharma Holding AB (publ) announces today that the annual report for 2018 has been published and is available on the company’s website: https://vicorepharma.com/investors/#reports

The annual report shows that the publication date for the interim report quarter three 2019 has been changed to November 8, 2019 from the previously announced date, October 18, 2019.

For further information, please contact:

Hans Jeppsson, CFO, tel: +46 70-553 14 65, moc.a1569066060mrahp1569066060eroci1569066060v@nos1569066060sppej1569066060.snah1569066060

This information is information that Vicore Pharma Holding AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 08:00 CET on 12 April 2019.

About Vicore Pharma Holding AB (publ)
Vicore Pharma is a Swedish rare disease company focused on interstitial lung diseases and related indications. The Company currently has two drug development programs, VP01 and VP02. 

VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (“IPF”). As a result of the acquisition of INIM Pharma AB in August 2018, the Company’s pipeline was expanded with a second drug development program, VP02. VP02 is based on a new formulation and delivery route of an existing immunomodulatory compound (an “IMiD”). VP02 focuses on IPF with regards to both the underlying disease and the severe cough associated to IPF. C21 and IMiD are also evaluated for other indications within interstitial lung diseases. The acquisition of INIM Pharma meant an expansion of Vicore Pharma’s operation and that the Company’s strategy focused on developing drugs for the treatment of rare and severe lung diseases. VP01 will perform the expanded dose escalating Phase I study and  then start the Phase IIa study in IPF patients during the second half of 2019. VP02 is entering a phase of optimization of formulation before local tolerability studies will commence. The first clinical studies with VP02 are expected to start in 2020. 

The company’s share (VICO) is listed for trading on Nasdaq First North in Stockholm. The company´s certified adviser is Erik Penser Bank, telephone: +46 8 463 83 00, e-mail: es.re1569066060snep@1569066060resiv1569066060dadei1569066060fitre1569066060c1569066060. For more information, see www.vicorepharma.com

Vicore Pharma Annual Report 2018


Source: Vicore Pharma